Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy

Journal of Investigative Medicine

Volumn 61, Issue 2, 2013, Pages 256-264

  Kobori, Hiroyuki ^a   Kamiyama, Masumi ^a   Harrison Bernard, Lisa M ^b   Navar, L Gabriel ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensinogen; Diabetic nephropathy; Kidney; Renin angiotensin system

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; AMLODIPINE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PLACEBO; PROSTAGLANDIN F2 ALPHA; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; URINARY EXCRETION; URINE LEVEL; ARTICLE; CLINICAL OUTCOME; KIDNEY PROXIMAL TUBULE; NEPHRON;

ANGIOTENSINOGEN; ANIMALS; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY CORTEX; MICE; PEPTIDYL-DIPEPTIDASE A; RATS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 85006847162     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31827c28bb     Document Type: Conference Paper

References (106)

1. Joss N, Paterson KR, Deighan CJ, et al. Diabetic nephropathy: how effective is treatment in clinical practice? QJM. 2002;95:41-49.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
3. Bays HE, Bazata DD, Clark NG, et al. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the us population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). BMC Public Health. 2007;7:277.
4. National Diabetes Information Clearinghouse. A Service of the National Institute of Diabetes and Digestive and Kidney Diseases. The National Institutes of Health, 2007.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among us adults: findings from the third national health and nutrition examination survey. JAMA. 2002;287:356-359.
6. Mitchell KD, Navar LG. Intrarenal actions of angiotensin II in the pathogenesis of experimental hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1995:1437-1450.
7. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59:251-287.
8. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003;14:274-281.
9. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G proteinYcoupled receptor MAS. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
10. Navar LG, Prieto-Carrasquero MC, Kobori H. Chapter 1: molecular aspects of the renal renin-angiotensin system. In: Re RN, DiPette DJ, Schiffrin EL, et al, eds. Molecular Mechanisms in Hypertension. Oxfordshire, UK: Taylor & Francis Medical; 2006:3-14.
11. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation. 1994;89:493-498.
12. Baltatu O, Silva JA Jr, Ganten D, et al. The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension. 2000;35:409-412.
13. Dell'Italia LJ, Meng QC, Balcells E, et al. Compartmentalization of angiotensin II generation in the dog heart evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest. 1997;100:253-258.
14. Mazzocchi G, Malendowicz LK, Markowska A, et al. Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats. Am J Physiol Endocrinol Metab. 2000; 278:E1027YE1030.
15. Danser AH, Admiraal PJ, Derkx FH, et al. Angiotensin I-to-II conversion in the human renal vascular bed. J Hypertens. 1998;16:2051-2056.
16. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
17. Navar LG, Harrison-Bernard LM, Nishiyama A, et al. Regulation of intrarenal angiotensin II in hypertension. Hypertension. 2002; 39:316-322.
18. Ingelfinger JR, Zuo WM, Fon EA, et al. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest. 1990;85:417-423.
19. Kamiyama M, Garner MK, Farragut KM, et al. The establishment of a primary culture system of proximal tubule segments using specific markers from normal mouse kidneys. Int J Mol Sci. 2012;13:5098-5111.
20. Kamiyama M, Farragut KM, Garner MK, et al. Divergent localizations of angiotensinogen mRNA and protein in proximal tubular segments of normal rat kidney. J Hypertens. 2012;30:2365-2372.
21. Terada Y, Tomita K, Nonoguchi H, et al. Pcr localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney. Kidney Int. 1993;43:1251-1259.
22. Richoux JP, Cordonnier JL, Bouhnik J, et al. Immunocytochemical localization of angiotensinogen in rat liver and kidney. Cell Tissue Res. 1983;233:439-451.
23. Darby IA, Congiu M, Fernley RT, et al. Cellular and ultrastructural location of angiotensinogen in rat and sheep kidney. Kidney Int. 1994;46:1557-1560.
24. Darby IA, Sernia C. In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys. Cell Tissue Res. 1995;281:197-206.
25. Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol. 2001;12:431-439.
26. Pohl M, Kaminski H, Castrop H, et al. Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem. 2010;285:41935-41946.
27. Leyssac PP. Changes in single nephron renin release are mediated by tubular fluid flow rate. Kidney Int. 1986;30:332-339.
28. Yanagawa N, Capparelli AW, Jo OD, et al. Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture. Kidney Int. 1991;39:938-941.
29. Henrich WL, McAllister EA, Eskue A, et al. Renin regulation in cultured proximal tubular cells. Hypertension. 1996;27:1337-1340.
30. Moe OW, Ujiie K, Star RA, et al. Renin expression in renal proximal tubule. J Clin Invest. 1993;91:774-779.
31. Sibony M, Gasc JM, Soubrier F, et al. Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme. Hypertension. 1993;21:827-835.
32. Schulz WW, Hagler HK, Buja LM, et al. Ultrastructural localization of angiotensin IYconverting enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubule of the human kidney. Lab Invest. 1988;59:789-797.
33. Vio CP, Jeanneret VA. Local induction of angiotensin-converting enzyme in the kidney as a mechanism of progressive renal diseases. Kidney Int Suppl. 2003;64:S57YS63.
34. Casarini DE, Boim MA, Stella RC, et al. Angiotensin IYconverting enzyme activity in tubular fluid along the rat nephron. Am J Physiol. 1997;272:F405YF409.
35. Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067-3075.
36. Soler MJ, Ye M, Wysocki J, et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296: F398YF405.
37. Park S, Bivona BJ, Kobori H, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J physiol Renal Physiol. 2010;298:F37YF48.
38. Anderson S. Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab. 1998;24:406-411.
39. Harrison-Bernard LM, Imig JD, Carmines PK. Renal AT1 receptor protein expression during the early stage of diabetes mellitus. Int J Exp Diabetes Res. 2002;3:97-108.
40. Zimpelmann J, Kumar D, Levine DZ, et al. Early diabetes mellitus stimulates proximal tubule renin mrna expression in the rat. Kidney Int. 2000;58:2320-2330.
41. Kamiyama M, Urusihara M, Morikawa T, et al. Augmented intrarenal angiotensinogen mRNA expression parallels renal dysfunction in patients with type 2 diabetes [abstract]. Hypertension. 2010;56:e135.
42. Wehbi GJ, Zimpelmann J, Carey RM, et al. Early streptozotocinYdiabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol. 2001;280:F254YF265.
43. Kang JJ, Toma I, Sipos A, et al. The collecting duct is the major source of prorenin in diabetes. Hypertension. 2008;51:1597-1604.
44. Nagai Y, Yao L, Kobori H, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol. 2005;16:703-711.
45. Delete in proof.
46. Suzaki Y, Ozawa Y, Kobori H. Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in zucker diabetic fatty rats. Int J Biol Sci. 2007;3:40-46.
47. Miyata K, Ohashi N, Suzaki Y, et al. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2008;35:922-927.
48. Lorenz JN. Chymase: the other ACE? Am J Physiol Renal Physiol. 2010;298:F35YF36.
49. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
50. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK prospective diabetes study group. BMJ. 1998;317:713-720.
51. Schmieder RE. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens Suppl. 2006;24:S31YS35.
52. Parving HH, Lehnert H, Brochner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study G. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
53. Ruggenenti P, Fassi A, Ilieva AP, et al. Bergamo Nephrologic Diabetes Complications Trial I. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-1951.
54. Agodoa LY, Appel L, Bakris GL, et al. African American Study of Kidney Disease and Hypertension Study G. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
55. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
56. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851-860.
57. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
58. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
59. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-917.
60. Ingelfinger Jr. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes. N Engl J Med. 2011;364:970-971.
61. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the united states. JAMA. 2007;298:2038-2047.
62. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med. 1993;329:977-986.
63. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285-2293.
64. Wolkow PP, Niewczas MA, Perkins B, et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol. 2008;19:789-797.
65. Gould AB, Green D. Kinetics of the human renin and human substrate reaction. Cardiovasc Res. 1971;5:86-89.
66. Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension. 1996;27:465-475.
67. Ding Y, Davisson RL, Hardy DO, et al. The kidney androgen-regulated protein promoter confers renal proximal tubule cellYspecific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice. J Biol Chem. 1997;272:28142-28148.
68. Kimura S, Mullins JJ, Bunnemann B, et al. High blood pressure in transgenic mice carrying the rat angiotensinogen gene. EMBO J. 1992;11:821-827.
69. Fukamizu A, Sugimura K, Takimoto E, et al. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem. 1993;268:11617-11621.
70. Bohlender J, Menard J, Ganten D, et al. Angiotensinogen concentrations and renin clearance: implications for blood pressure regulation. Hypertension. 2000;35:780-786.
71. Smithies O. Theodore cooper memorial lecture. A mouse view of hypertension. Hypertension. 1997;30:1318-1324.
72. Merrill DC, Thompson MW, Carney CL, et al. Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest. 1996;97:1047-1055.
73. Kobori H, Ozawa Y, Satou R, et al. Kidney-specific enhancement of Ang II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol. 2007;293: F938YF945.
74. Sachetelli S, Liu Q, Zhang SL, et al. Ras blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int. 2006;69:1016-1023.
75. Lavoie JL, Lake-Bruse KD, Sigmund CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol. 2004;286: F965YF971.
76. Smithies O, Kim HS. Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci U S A. 1994;91:3612-3615.
77. Kim HS, Krege JH, Kluckman KD, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995;92:2735-2739.
78. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest. 1997;99:1786-1797.
79. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71: 169-180.
80. Zhao YY, Zhou J, Narayanan CS, et al. Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. Hypertension. 1999;33:108-115.
81. Ishigami T, Umemura S, Tamura K, et al. Essential hypertension and 5′ upstream core promoter region of human angiotensinogen gene. Hypertension. 1997;30:1325-1330.
82. Schunkert H, Ingelfinger JR, Jacob H, et al. Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. Am J Physiol. 1992;263:E863YE869.
83. Kobori H, Prieto-Carrasquero MC, Ozawa Y, et al. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin IIYdependent hypertension. Hypertension. 2004;43:1126-1132.
84. Kobori H, Nishiyama A, Harrison-Bernard LM, et al. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension. 2003;41:42-49.
85. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 2002;61:579-585.
86. Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of angiotensinogen expression in angiotensin IIYdependent hypertension. Hypertension. 2001;37:1329-1335.
87. Kobori H, Nishiyama A. Effects of tempol on renal angiotensinogen production in Dahl saltYsensitive rats. Biochem Biophys Res Commun. 2004;315:746-750.
88. Kobori H, Nishiyama A, Abe Y, et al. Enhancement of intrarenal angiotensinogen in Dahl saltYsensitive rats on high salt diet. Hypertension. 2003;41:592-597.
89. Kobori H, Ozawa Y, Suzaki Y, et al. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol. 2005;16:2073-2080.
90. Anderson S, Jung FF, Ingelfinger Jr. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol. 1993;265:F477YF486.
91. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol. 2005;288:F1183YF1190.
92. Leehey DJ, Singh AK, Bast JP, et al. Glomerular renin angiotensin system in streptozotocin diabetic and zucker diabetic fatty rats. Transl Res. 2008;151:208-216.
93. Kobori H, Katsurada A, Ozawa Y, et al. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun. 2007;358:156-163.
94. Takamatsu M, Urushihara M, Kondo S, et al. Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy. Pediatr Nephrol. 2008;23:1257-1267.
95. Kobori H, Ozawa Y, Suzaki Y, et al. Young scholars award lecture: intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens. 2006;19:541-550.
96. Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci. 2012;119:314-323.
97. Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin- aldosterone system and renal injury in obesity and the metabolic syndrome. Cur Hyperten Rep. 2012;14:160-169.
98. Katsurada A, Hagiwara Y, Miyashita K, et al. Novel sandwich elisa for human angiotensinogen. Am J Physiol Renal Physiol. 2007;293: F956YF960.
99. Yamamoto T, Nakagawa T, Suzuki H, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007;18:1558-1565.
100. Kobori H, Ohashi N, Katsurada A, et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens. 2008;2:349-354.
101. Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26:170-177.
102. Urushihara M, Kondo S, Kagami S, et al. Urinary angiotensinogen accurately reflects intrarenal renin-angiotensin system activity. Am J Nephrol. 2010;31:318-325.
103. Kobori H, Alper AB, Shenava R, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009;53:344-350.
104. Kobori H, Urushihara M, Xu JH, et al. Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study). J Hypertens. 2010;28:1422-1428.
105. Ogawa S, Kobori H, Ohashi N, et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights. 2009;4:97-102.
106. Saito T, Urushihara M, Kotani Y, et al. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci. 2009;338:478-480.